(R5) virus predominates throughout most of HIV disease, and ∼80% of treatment-naive individuals infected with subtype B virus have exclusively R5 virus [1, 2] . Human genetic restrictions in CCR5 expression provide protection against HIV infection and disease progression without apparent adverse consequences [3] [4] [5] . Thus, therapeutic blockade of CCR5 presents a novel opportunity for inhibiting HIV. Vicriviroc (SCH-D, SCH 417690) is a small-molecule CCR5 antagonist with potent in vitro activity against a wide range of HIV subtypes [6] . In clinical trials, vicriviroc effectively decreased viral load and was well tolerated [7] [8] [9] .
Vicriviroc, similar to maraviroc, is an allosteric inhibitor of HIV CCR5 coreceptor binding [10, 11] . Both drugs induce conformational changes when they bind to a pocket formed by the transmembrane domains of the receptor near the cell surface [12] . Phenotypic resistance to CCR5 antagonists can arise through alterations in the viral envelope that allow the virus to utilize either the inhibitor-bound form of CCR5 or the alternate coreceptor CXCR4. Multiple, independent in vitro serial passage studies with vicriviroc and maraviroc revealed that most viruses that developed phenotypic resistance to either inhibitor remained exclusively R5 [13] [14] [15] . For both compounds, resistance was characterized by reductions in the maximum achievable levels of suppression of viral replication rather than increases in the median inhibitory concentration (IC 50 ) [15] [16] [17] . Thus, in a classic dose response curve, the plateau that represents the maximum percent inhibition (MPI) is progressively lowered as the virus becomes increasingly resistant to drug therapy. Changes in susceptibility to CCR5 antagonists are usually accompanied by substitutions in gp120, and the variable domain 3 (V3) loop appears to play a critical role. However, substitutions outside this region, including in C4 and gp41, also contribute to the resistance phenotype [14, 18] .
Recently, Landovitz et al [8] reported the results of a phase 2 vicriviroc dose-finding study in treatment-naive subjects. The study was terminated early because of elevated failure rates in the 25-mg and 50-mg dose groups (the failure rate in the 75-mg dose group was similar to that in the control group, in which subjects were given efavirenz). The trough plasma concentration (C min ) appeared to correlate with decreased viral load at day 14, with subjects with virological response having higher C min values than those of the subjects with virological failure [8] . Genotypic resistance testing performed for the 26 vicriviroc-treated subjects with virological failure showed that the 22 subjects with reportable genotypes at the end of treatment (EOT) all had virus with mutations indicative of lamivudine resistance.
To determine whether changes in susceptibility to vicriviroc were associated with treatment outcome in the above study [8] , in this study we performed tropism and susceptibility testing as well as population sequencing on viral isolates from plasma samples collected at baseline and while the subject was receiving treatment. For those viruses displaying reduced susceptibility to vicriviroc, clonal analyses were performed to determine whether specific sequence changes were associated with reduced susceptibility to vicriviroc.
METHODS

Study design.
Treatment-naive subjects with CD4 cell counts of у150 cells/mL, HIV type 1 (HIV-1) RNA loads of 15000 copies/mL (determined with the Roche Amplicor HIV-1 Monitor test), and R5 virus were randomized 1:1:1:1 for 14 d of monotherapy with vicriviroc (25, 50, or 75 mg once daily) or placebo. This was followed by 46 weeks of their assigned vicriviroc dose plus lamivudine and zidovudine in a twice-daily fixed-dose combination; subjects receiving placebo were switched to 600 mg of efavirenz once daily. Therapy was discontinued for subjects who experienced virological failure (defined as either HIV-1 RNA load of !1.0 log 10 copies/mL below the baseline level at week 4, HIV-1 RNA load of 150 copies/ mL at week 20, or HIV-1 RNA load rebounding to levels of 150 copies/mL after decreasing to levels below that limit). Institutional review boards at each site approved the study protocol, and all subjects provided voluntary written informed consent.
Drug susceptibility and tropism. Subjects who discontinued therapy underwent tropism testing and genotyping, as well as phenotypic testing for resistance to drugs in their regimen (testing was performed with Monogram Biosciences PhenoSense GT and Entry assays). Vicriviroc susceptibility was expressed as MPI, relative MPI, IC 50 , and fold change in IC 50 . From curves of percent inhibition versus log 10 drug concentration, the percent inhibition was calculated as [1 Ϫ (RLU in the presence of drug/RLU in the absence of drug)] ϫ 100, where RLU is the relative light unit. Inhibition curves were defined by the 4-parametric log-sigmoidal function:
where a is the percent inhibition at the top of the curve, b is the percent inhibition at the base of the curve, c is the percent inhibition at the center of the curve, and d is the curve tension ("slope"). Inhibition curves were fitted to the data by using a nonlinear least squares method, and a bootstrap method was used to calculate IC 50 values.
Envelope population sequencing. HIV-1 RNA was extracted from plasma samples by use of the QIAmp Viral RNA Mini kit (Qiagen). Full-length gp160 was amplified by means of reverse-transcription polymerase chain reaction (primers 5 -CACCGAAAGAGCAGAAGACAGTGGCAATGG and 5 -TCC-AGTCCCCCCTTTTCTTTTAAAAAGTGGC) followed by nested polymerase chain reaction (primers 5 -CACCGAAAGAGC-AGAAGACAGTGGCAATGG and 5 -TTTTGACCCATTGCC-ACCCATCTTATAGCAAA). Individual sequence fragments were assembled and edited using Sequencher software (version 4.6; Gene Codes) and aligned using BioEdit software (version 7.0.8.0; Ibis Therapeutics). The percentage of mutations in virus from each subject was calculated on the basis of the number of positions in gp160 that were changed from the baseline sequence. Viral gp160 population sequences were deposited in GenBank (GU252763-GU252812).
Envelope clonal analysis. Full-length gp160 clones were generated from baseline and EOT plasma samples, sequenced, and tested for susceptibility to vicriviroc in the PhenoSense Entry assay. Sequence alignments and phylogenetic trees were constructed using the VectorNTI AlignX program employing the Clustal W and neighbor-joining analytical methods [19] . NOTE. Data are from the P03802 study [8] . DM, dual mixed virus; IC 50 , median inhibitory concentration; MPI, maximum percent inhibition; PDVF, protocoldefined virological failure; R5, CCR5-tropic; V3, variable domain 3.
a Changes are indicated in boldface font. An asterisk indicates the location of a deletion (in a later sample) or an insertion (in a day 1 sample). b Relative MPI is the MPI value of the virus from the subject divided by the that of a control virus, evaluated in parallel. c Fold change in IC 50 is the IC 50 value of the virus from the subject divided by that of a control virus, evaluated in parallel. d Percentage of amino acid changes in gp160 population in end-of-treatment virus, compared with virus sequenced on day 1. e No tropism or susceptibility data are available for the end-of-treatment sample due to insufficient viral load f Subjects whose samples harbored resistant virus. g The fold change in IC 50 value could not be calculated because the MPI value was !50%.
All clonal sequences were deposited in GenBank (GU191348-GU191452).
RESULTS
Genotypic analysis of viral populations.
To determine whether vicriviroc treatment was associated with a specific pattern of amino acid changes or virological outcome, we sought to sequence gp160 from baseline and EOT samples from all enrolled subjects. However, due to sample loss and insufficient RNA titers in EOT samples, gp160 from only 23 vicriviroc-treated subjects and 2 placebo-treated subjects were sequenced. For each subject, the sequences from the baseline and EOT samples were aligned, and the percentage of amino acid changes across the entire envelope (Table 1 ) and within each variable loop ( Figure 1A ) was recorded. For the vicriviroc-treated subjects, the percentage of changes across the gp160 protein was 0.7%-22.7% (mean, 8.1%) and was similar to that observed for the 2 placebo-treated subjects (mean, 6.6%). In all paired samples, the majority of changes in gp120 occurred in the variable domain 1 (V1) and variable domain 2 (V2) loops ( Figure 1 ). Although there was no apparent correlation between treatment outcomes and the number or location of amino acid changes, the number of samples from subjects who received placebo and subjects who did not experience virological failure was too small to make any statistical comparisons. In samples from 14 of the 25 subjects whose samples were analyzed, 1 or more amino acid changes in the V3 loop between the baseline and EOT virus population were detected (Table 1) . However, no consistent pattern of changes was detected, and in most cases, changes in the V3 loop population sequence were not associated with a change in either tropism or vicriviroc susceptibility. Dual mixed (DM)/CXCR4-tropic (X4) virus was detected in EOT samples from 4 of the above-mentioned 25 subjects. In the 2 subjects (114 and 42) with virological failure, DM virus was detected at weeks 16 and 32, respectively, and virus from both EOT samples had multiple amino acid changes in the V3 loop. Virus from a third subject (130) had a DM phenotype at both baseline and EOT; virus from the later sample had a P13R mutation and a 2-amino acid insertion at positions 14 and 15 in V3. In contrast, in the fourth subject (100), who received placebo, virus shifted from R5 to DM by day 14 without any detectable V3 changes.
Among subjects infected with exclusively R5 virus, population sequencing did not reveal any specific changes in gp120 that were linked to treatment failure. Changes in gp41 were most commonly detected in the transmembrane and cytoplasmic tail regions as well as in the heptad repeat 2 domain ( Figure  1B ). However, similar to gp120, there was no clear pattern of changes or specific mutations associated with treatment failure in this analysis (data not shown).
Baseline susceptibility to vicriviroc and virological outcome. Baseline susceptibility parameters (IC 50 , fold change in IC 50 , MPI, and relative MPI) were analyzed to determine whether differences in vicriviroc susceptibility prior to treatment were correlated with clinical outcome. Phenotypic characterization of viral gp160 envelope. Vicriviroc susceptibility was assessed at baseline, at weeks 2 and 24, and at EOT. The relative MPI values at the different time points for all subjects are shown in Figure 2 . No reductions in vicriviroc susceptibility were observed in the viral population from any subject during the 2-week monotherapy period (Figure 2 ). By Figure 3 . Dose response curves of baseline and on-treatment virus from subject 243. Viral pools generated from subject 243 were evaluated for vicriviroc susceptibility with the PhenoSense Entry assay (Monogram Biosciences). The corresponding maximum percent inhibition and median inhibitory concentration values at baseline and at weeks 2, 24, and 33 were 96%, 98%, 97%, and 75%, respectively, and 7.4, 2.7, 1.9, and 2.9 nmol/L (nM), respectively. week 24, 1 subject (91) exhibited reduced susceptibility to vicriviroc, with a relative MPI value of 0.67 that decreased to 0.41 by week 48. Virus from subjects 8, 131, and 243 also had relative MPI values of !0.9 at EOT. At baseline, virus from all 4 of these subjects had relative MPI values of 10.99. For 3 of the 4 subjects, the changes in the relative MPI values were not mirrored by increases in the fold change in the IC 50 values. For example, in the dose response curves for subject 243, the IC 50 values for virus sampled at weeks 2, 24, and 33 were slightly lower than those at baseline, whereas the MPI value at week 33 was markedly decreased, compared with that at baseline (Figure 3) . For the exception, subject 91, the dose response curve for the EOT sample did not reach a plateau of 50% and the IC 50 value was reported as 1667 nmol/L (the highest concentration tested).
All 4 subjects initially achieved logarithmic decreases in viral load of 1.8-3.2 prior to virological breakthrough (Figure 4) . In 3 of the 4 subjects, R5 virus was detected at baseline and at EOT. In subject 91, a DM virus population was detected at a single time point, week 24, but R5 virus was detected at week 48. Virological breakthrough occurred prior to determination of phenotypic resistance to vicriviroc in all 4 subjects, and therefore it remains to be determined whether emergent vicriviroc resistance was a cause or a consequence of incomplete viral suppression.
No association between decreased vicriviroc plasma levels and development of phenotypic resistance. Overall, C min values of 1100 ng/mL were strongly predictive of virological success in this study [8] . To determine whether vicriviroc levels were associated with changes in susceptibility, we compared the C min values of the 4 subjects exhibiting phenotypic resistance with those of other subjects within the same dose group. None of the subjects in the low-dose group developed resistance, although this group received therapy for the shortest duration (mean, 24.4 weeks; range, 7.9-53.4 weeks). The population mean steady state C min values for the 50-mg and 75-mg dose groups were 44 ng/mL (range, 17-102 ng/mL) and 77 ng/mL (range, 27-249 ng/mL), respectively. Subjects 8 and 243 (in the 50-mg dose group) and subjects 91 and 131 (in the 75-mg dose group) had mean C min values of 24, 77, 95, and 237 ng/mL, respectively. Therefore, with the exception of subject 8, low vicriviroc trough concentration was not associated with phenotypic resistance to vicriviroc in these subjects.
Clonal analysis of gp160 from virus exhibiting reduced susceptibility to vicriviroc. To identify the molecular correlates associated with loss of vicriviroc susceptibility in the 4 subjects detailed above, 9-12 full-length gp160 clones were generated from baseline and EOT plasma samples. After construction of phylogenetic trees, the relative heterogeneity of virus populations were assessed by calculating the average branch length of individual clones from each time point. For subjects 8, 91, and 243, the mean branch lengths of the EOT clones were 75%-90% shorter than those of the corresponding baseline clones, which suggests that a reduction in heterogeneity had occurred while receiving therapy ( Figure 5A ). In addition, for all subjects, the EOT clones clustered together and were distinct from the baseline clones; Figure 5B provides a representative phylogenetic tree for subject 91. Interestingly, the clones from week 48 from subject 91 were more closely related to the baseline sequences than to the clones from week 24, which suggests that resistance development did not follow a linear path over time. Table 2 ). These changes in susceptibility were associated with a number of amino acid substitutions in the V3 loop, including Q18E and D25G; a G17A mutation was associated with further reductions in vicriviroc susceptibility. Previously, we and others observed a K10R substitution in the V3 loops in some vicriviroc-resistant viruses [13, 14] . However, both in subject 243 and in subjects 8 and 131, the K10R substitution was detected in fully susceptible baseline and/or EOT clones, which suggests that this substitution alone does not confer vicriviroc resistance. In contrast to subject 243, the baseline clones from subjects 8, 91, and 131 exhibited a wide range of relative MPI values (0.52-11). Despite the apparent reduced susceptibility of some of the baseline clones, the viruses that emerged after vicriviroc treatment were genotypically distinct from the baseline clones and showed further reductions in susceptibility. For example, 1 baseline clone from subject 91, with a relative MPI value of 0.52 and I2T and E32Q substitutions in the V3 loop, was not represented in subsequent clones from weeks 24 or 48. This suggests that although some clones that were present at baseline exhibited reduced susceptibility to vicriviroc, they did not appear to expand or persist after initiation of vicriviroc therapy. In regard to sequence changes in the EOT clones that exhibited decreased relative MPI values, there were very few substitutions that were conserved across all clones from a given individual subject, and between individual subjects, there was no consistent pattern of mutations in the V3 loop (Table 2 ) or in any other region of gp160 (data not shown). Even clones with identical V3 loop sequences exhibited a wide range of relative MPI values, presumably because of changes outside the V3 loop that influence susceptibility and/or viral infectivity. In addition, other factors such as viral titer or receptor expression have been shown to affect MPI values [14, 15, 19] .
DISCUSSION
In this study, we examined the phenotypic, genotypic, and pharmacokinetic factors that contributed to virological failure and evolution of drug resistance in treatment-naive subjects in a phase 2 study of vicriviroc. Emergence of DM/X4 virus was not a significant factor, because only 2 subjects with virological breakthrough had confirmed DM virus at the conclusion of the study. In addition, baseline susceptibility parameters (either relative MPI or fold change in IC 50 ) to vicriviroc were similar among subjects with and subjects without virological breakthrough in the study. However, as detailed previously, the primary contributory factor to virological failure was inadequate vicriviroc plasma levels; the majority of treatment failures occurred in the 2 low-dose cohorts, and subjects for whom treatment failed were exposed to lower drug concentrations than were subjects who maintained viral suppression [9] . Despite their low plasma levels of vicriviroc, phenotypic resistance to vicriviroc was detected in only 4 of the 26 subjects with virological failure. In contrast, virus from all 22 of the subjects with virological failure whose samples were successfully genotyped had acquired reverse transcriptase mutations to lamivudine and, in 1 subject, also to zidovudine. These data suggest that the barrier to resistance development is higher for vicriviroc than for the reverse transcriptase inhibitors.
The earliest time point at which a marked reduction in susceptibility to vicriviroc was detected was 24 weeks. A population pharmacokinetic evaluation confirmed that the vicriviroc plasma levels in 3 of the 4 subjects with phenotypically resistant virus exceeded the mean plasma concentrations for subjects in the same dose group, which suggests that low vicriviroc ex- posure per se was not a major contributory factor for vicriviroc resistance. In addition, no vicriviroc resistance was observed among subjects in the low-dose group. Unlike resistance to reverse transcriptase, protease, and fusion inhibitors, which are all competitive inhibitors, phenotypic resistance to vicriviroc, an allosteric inhibitor, was not manifested as an increase in the fold change in the IC 50 value. Instead, virus from the 4 subjects detailed above exhibited a marked decrease in MPI and relative MPI values at EOT, whereas the corresponding fold change in IC 50 values decreased relative to baseline in 3 subjects (the dose response curve for the EOT sample from the fourth subject did not reach 50% inhibition at the highest drug concentration tested). These decreases in MPI and relative MPI values in these 4 subjects are consistent with the phenotypic changes in vicriviroc susceptibility that were previously observed in vitro [14] . For example, resistant virus from a single subject in the AIDS Clinical Trials Group 5211 study reported by Tsabris et al [17] , as well as maravirocresistant viruses [15] , all exhibited decreases in MPI value, rather than increases in IC 50 value. In contrast, Kitrinos et al [20] recently reported that envelope clones derived from some aplaviroc-treated subjects exhibited 13-fold increases in IC 50 values with no change in MPI value; the same report also described clones from other subjects that did exhibit decreases in MPI value. This apparent difference in resistance profiles of vicriviroc and aplaviroc may reflect differences in the compound binding site on CCR5, because mutagenesis studies demonstrated that aplaviroc binds to a site on CCR5 that overlaps with but is distinct from that of vicriviroc and maraviroc [12] . Therefore, it is conceivable that aplaviroc behaves like a competitive (rather than an allosteric) inhibitor for some HIV strains and as such the IC 50 value shifts would be the expected marker of phenotypic resistance based on models of G proteincoupled receptor-ligand binding [21] . However, for vicriviroc, which acts as an allosteric antagonist of CCR5, a decrease in MPI value, and not in IC 50 value, appears to be a more relevant measure of reduced susceptibility. More data, however, will be needed to determine the appropriate cutoff value for MPI that is predictive of virological success in the clinic.
To better understand the molecular basis for the changes in vicriviroc susceptibility, multiple gp160 clones were generated from viral swarms that exhibited reduced susceptibility to vicriviroc. Consistent with findings from similar studies that used other CCR5 antagonists, we found no conserved intersubject pattern of mutations in gp160 that were associated with reduced susceptibility. Although changes in the V3 loop, a key region for env-CCR5 binding, were the most strongly associated with a loss in vicriviroc susceptibility, clones with identical V3 loop sequences exhibited a wide range of MPI values, indicating that residues outside this region are also important in mediating changes in susceptibility and viral infectivity. This observation is consistent with recent reports by Ogert et al [14] and Anastassopoulou et al [18] , who demonstrated that mutations in C4 and gp41, respectively, were important for phenotypic resistance to CCR5 antagonists. Regions such as V1/V2, C4, and V4 that form the bridging sheet are thought to mediate functional interactions with V3 and play a role in CCR5 binding. The possibility that interactions between different domains allow alternative envelope conformations suggests that multiple pathways to resistance are possible and could explain the genetic diversity seen in the resistant isolates.
The reduction in gp160 sequence heterogeneity among virus with reduced susceptibility suggests these viruses arose by expansion of a minor subpopulation that was incompletely inhibited by vicriviroc. This hypothesis is supported by in vitro resistance analyses with the CCR5 antagonist, AD101, a precursor of vicriviroc [22, 23] . Envelope sequences from infected cell cultures became increasingly homogeneous after drug selection, and key substitutions associated with low-level resistance were essentially fixed within 4 passages; a further 12 passages were required to select for additional mutations conferring high-level resistance.
The underlying factors contributing to the development of vicriviroc resistance remain unclear. Although baseline susceptibility measurements showed a range of relative MPI and fold change in IC 50 values, these were not correlated with clinical outcome or development of resistance to vicriviroc in this study. Likewise, resistance to vicriviroc was not associated with low vicriviroc plasma concentrations. A major limitation of this study was the small number of subjects in whom vicrivirocresistant HIV was developed. Although we have identified envelope regions critical to resistance, we have yet to document specific residues or mutational patterns that would allow for genotypic prediction of vicriviroc resistance. Analysis of larger cohorts is necessary to further understand the factors contributing to development of resistance and how to define resistance in a clinical setting.
